REVIEWSThe use of recombinant activated factor VII in congenital and acquired von Willebrand diseaseFranchini, Massimoa; Veneri, Dinob; Lippi, GiuseppecAuthor Information aServizio di Immunoematologia e Trasfusione – Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy bDipartimento di Medicina Clinica e Sperimentale, Sezione di Ematologia, Italy cIstituto di Chimica e Microscopia Clinica, Dipartimento di Scienze Biomediche e Morfologiche, Università di Verona, Verona, Italy Received 25 May, 2006 Revised 16 August, 2006 Accepted 23 August, 2006 Correspondence and requests for reprints to Massimo Franchini, MD, Servizio di Immunoematologia e Trasfusione – Centro Emofilia, Ospedale Policlinico, Piazzale L.Scuro 10, 37134 Verona, Italy Tel: +39 45 8073610; fax: +39 45 8073612; e-mail: email@example.com Blood Coagulation & Fibrinolysis: November 2006 - Volume 17 - Issue 8 - p 615-619 doi: 10.1097/MBC.0b013e3280100d1e Buy Metrics Abstract Recombinant activated factor VII (NovoSeven), a novel hemostatic agent originally developed for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors, has been recently employed with benefit for the management of hemorrhages in other nonhemophilic congenital and acquired hemostatic abnormalities. This review focuses on the use of this drug in acquired and congenital von Willebrand disease. The analysis of the literature data shows that recombinant activated factor VII is an effective agent for the treatment of refractory bleeding in von Willebrand disease patients and for the treatment or prevention of bleeding in those patients with alloantibodies or autoantibodies against von Willebrand factor. Further studies are needed, however, to assess its safety and to optimize the dosages and regimens of therapy in such patients. © 2006 Lippincott Williams & Wilkins, Inc.